Shares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $27.86 and last traded at $28.26, with a volume of 519809 shares traded. The stock had previously closed at $29.40.
Analyst Ratings Changes
A number of brokerages recently issued reports on IMCR. Guggenheim downgraded shares of Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. Mizuho cut shares of Immunocore from an "outperform" rating to a "neutral" rating and decreased their price objective for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 target price (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. UBS Group assumed coverage on Immunocore in a research report on Thursday, October 24th. They set a "sell" rating and a $24.00 price objective for the company. Finally, Needham & Company LLC cut their target price on Immunocore from $78.00 to $71.00 and set a "buy" rating on the stock in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $65.64.
View Our Latest Report on Immunocore
Immunocore Stock Performance
The stock has a 50 day simple moving average of $32.14 and a two-hundred day simple moving average of $34.86. The company has a market cap of $1.42 billion, a PE ratio of -29.92 and a beta of 0.73. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to analysts' expectations of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm's revenue for the quarter was up 23.7% on a year-over-year basis. During the same period last year, the firm earned ($0.59) EPS. Equities analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after buying an additional 668,382 shares during the period. FMR LLC raised its position in Immunocore by 0.5% in the third quarter. FMR LLC now owns 4,836,040 shares of the company's stock worth $150,546,000 after acquiring an additional 23,436 shares in the last quarter. Primecap Management Co. CA lifted its holdings in Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock valued at $76,954,000 after acquiring an additional 520,950 shares during the period. Bellevue Group AG grew its stake in shares of Immunocore by 4.4% during the 3rd quarter. Bellevue Group AG now owns 1,205,464 shares of the company's stock worth $37,526,000 after purchasing an additional 50,810 shares during the period. Finally, Armistice Capital LLC increased its holdings in shares of Immunocore by 495.1% in the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company's stock valued at $33,077,000 after purchasing an additional 812,000 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.
About Immunocore
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
